Showing posts with label abstract. Show all posts
Showing posts with label abstract. Show all posts

Saturday, September 26, 2026

In silico analysis of #pH stabilising #mutations of #hemagglutinin of #influenza A virus #H5N1 clade 2.3.4.4b

 


Abstract

Highly pathogenic avian influenza A(H5N1) viruses are expanding their host range among mammals, raising concerns about their pandemic potential. Building on recently published deep mutational scanning data, we show that hemagglutinin retains structural plasticity to increase acid stability through independent mechanisms, including modulation of electrostatic interactions, hydrogen-bonding networks and hydrophobic packing that may facilitate human adaptation. These findings illustrate how structural analyses can strengthen genomic surveillance for pandemic risk assessment.

Source: 


Link: https://doi.org/10.1038/s44298-026-00236-y

____

Early insights into predicted efficacy of #Ebola monoclonal #antibodies for the 2026 #Bundibugyo virus disease #outbreak

 


Abstract

The 2026 Bundibugyo virus disease (BVD) outbreak in the DRC and Uganda raises urgent questions about the efficacy of existing Ebola virus (EBOV) monoclonal antibodies (mAbs) against Bundibugyo virus (BDBV). Here, we perform genomic and structural analyses of 44 BDBV sequences, including 12 from the 2026 outbreak, to assess mAb binding to the viral glycoprotein (GP). While the MBP134 cocktail epitopes remain conserved, mAb114 (Ebanga) binding is compromised by E112D and P116A mutations, causing off-target binding and reduced affinity. Structural modeling of Inmazeb shows that while Odesivimab maintains epitope binding, Atoltivimab and Maftivimab fail to bind their designated sites individually, though the complete trimeric cocktail demonstrates BDBV synergistic binding. These computational models predict mAb114 efficacy against BDBV may be compromised due to epitope mutations affecting binding affinity, whereas MBP134 retains conserved targeting and holds promise as a broadly protective therapeutic. The complex binding behavior of Inmazeb components points to the importance of antibody combinatorial effects for treatment efficacy. These observations warrant urgent experimental validation through neutralization assays.

Source: 


Link: https://doi.org/10.1038/s41467-026-78077-9

____

Highly Pathogenic Avian #Influenza Viruses #H5N1 and #H5N5 in Red #Foxes (Vulpes vulpes) in #Norway during 2022-2024

 


Abstract

Since 2020, highly pathogenic avian influenza (HPAI) A(H5Nx) clade 2.3.4.4b viruses have spread globally, causing extensive outbreaks in domestic and wild birds. Increased circulation has resulted in frequent spillover to mammals, and occasional mammal-to-mammal transmission. Although human infections remain rare, the zoonotic potential of these viruses continues to be a public health concern. We investigated six cases of HPAI in red foxes (Vulpes vulpes) in Norway during 2022-2024 and identified infections with H5N1 and H5N5 viruses. Pathological and virological investigations demonstrated systemic infection, with prominent lesions in the brain and/or lungs. Phylogenetic analyses showed high similarity between viruses detected in foxes and those concurrently circulating in wild birds. The mammalian adaptation marker PB2:E627K was identified in one H5N1 virus and as a minority variant in a second H5N1 virus.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Norwegian Veterinary Institute, 12314

Source: 


Link: https://doi.org/10.64898/2026.09.25.754393

____

#Coronavirus Disease Research #References (AMEDEO, September 26 '26)

 


    Clin Infect Dis

  1. LEWIS NM, Cleary S, Harker EJ, Safdar B, et al
    Influenza vaccine effectiveness against influenza A-associated hospitalization and severe in-hospital outcomes among adults in the United States, 2024-2025.
    Clin Infect Dis. 2026 Sep 26:ciag540. doi: 10.1093.
    PubMed         Abstract available


    Int J Infect Dis

  2. MICHELE P, Serena M, Anna B, Alberto Z, et al
    Post-pandemic re-establishment of respiratory virus seasonality and molecular epidemiology of Rhinovirus/Enterovirus in Northern Italy: a three-year surveillance study (2023-2026).
    Int J Infect Dis. 2026 Sep 21:109132. doi: 10.1016/j.ijid.2026.109132.
    PubMed         Abstract available


    J Infect

  3. RAO X, Fan H, Ding S, Zhang C, et al
    Meta-analysis of Maternal SARS-CoV-2 Infection and Child Growth and Development.
    J Infect. 2026 Sep 24:106869. doi: 10.1016/j.jinf.2026.106869.
    PubMed        


    J Med Virol

  4. CHEN Y, Shang M, Dou S, Wang X, et al
    Changes in Dengue Epidemiology in China Before, During, and After COVID-19 2015-2024: A Retrospective National Surveillance and Spatiotemporal Study.
    J Med Virol. 2026;98:e71162.
    PubMed         Abstract available


    J Virol

  5. PARK H-S, Matsuoka Y, Santos C, Duncan EF, et al
    Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters.
    J Virol. 2026 Sep 24:e0093826. doi: 10.1128/jvi.00938.
    PubMed         Abstract available


    JAMA

  6. ANDERER S
    FDA Approves Updated COVID-19 Vaccines for 2026-2027.
    JAMA. 2026 Sep 25. doi: 10.1001/jama.2026.14727.
    PubMed        


    Lancet

  7. CALDERON-LARRANAGA S, Bakhti R, Etemadi M, Fakih L, et al
    The NUS-Lancet PRIME Commission: transforming pandemic readiness for equity.
    Lancet. 2026;408:1211-1274.
    PubMed        


    Radiology

  8. HAN X, Guo Y, Fan W, Nie Z, et al
    Five-year Quantitative Chest CT and Hyperpolarized Xenon 129 Ventilation MRI Findings in Survivors of COVID-19 Pneumonia.
    Radiology. 2026;320:e261153.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, September 26 '26)

 


    Arch Virol

  1. LEE K, An SH, Heo GB, Lee YJ, et al
    Correction: Genomic characterization of H6N1 avian influenza viruses from wild birds and domestic ducks in the republic of Korea and Mongolia (2022-2024).
    Arch Virol. 2026;171:283.
    PubMed        


    Biochem Soc Trans

  2. CAWTHORNE W, Zhang Y, Val N, Nelson M, et al
    Unmasking programmed cell death in rhinovirus-driven asthma pathology.
    Biochem Soc Trans. 2026;54:1359-1373.
    PubMed         Abstract available


    BMC Pediatr

  3. SU L, Chen HS, Qiu WL, Zhong WM, et al
    The rationality of drug treatment and clinical characteristics in children with SARS-CoV-2 infection: a retrospective analysis.
    BMC Pediatr. 2026;26:894.
    PubMed         Abstract available


    Epidemiol Infect

  4. MITCHELL E, Zhu H, Fitzpatrick T, Majoe A, et al
    Social disparities and the COVID-19, influenza, and RSV 'tripledemic' in Ontario, Canada: A population-based study.
    Epidemiol Infect. 2026;154:e117.
    PubMed         Abstract available


    Eur J Epidemiol

  5. ANDREASSON J, Bennet L, Bjork J, Dietler D, et al
    SARS-CoV-2 infection as a trigger of type 2 diabetes in adults: a population-based cohort study in Sweden using a double negative control design.
    Eur J Epidemiol. 2026;41:959-967.
    PubMed         Abstract available

  6. HELLE S, Tanskanen AO, Danielsbacka M
    The decade of double-trouble: live birth and stillbirth sex ratio variation in Finland during the COVID-19 pandemic and Russia's attack on Ukraine.
    Eur J Epidemiol. 2026;41:1019-1028.
    PubMed         Abstract available


    J Infect Dis

  7. SCHUMER C, Mann AJ, Fourati S, Lukas P, et al
    Viral Dynamics of the Respiratory Syncytial Virus During Experimental Human Challenge: Implication for Transmission and Protection.
    J Infect Dis. 2026;234:407-416.
    PubMed         Abstract available

  8. ALKARKOUKLY S, Hambo S, Menk M, Spieth P, et al
    Regulatory T-Cell Notch4 Expression Correlates With Mortality in Patients Hospitalized With COVID-19.
    J Infect Dis. 2026;234:396-406.
    PubMed         Abstract available

  9. ENGELMANN I, Pisoni A, Mille C, Ayadi M, et al
    Age-Dependent Clinical and Molecular Rhinovirus Epidemiology, 2018-2023.
    J Infect Dis. 2026;234:417-426.
    PubMed         Abstract available

  10. MCCULLOCH DJ, Khawaja F, Tverdek FP, Ford ES, et al
    First Report on Remdesivir Use for the Treatment of Respiratory Syncytial Virus in Five Allogeneic Hematopoietic Cell Transplant Recipients.
    J Infect Dis. 2026;234:e552-e555.
    PubMed         Abstract available

  11. MARCHAL A, Kerdiles T, Perrin A, Gervais A, et al
    High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons.
    J Infect Dis. 2026;234:e515-e521.
    PubMed         Abstract available

  12. ROEN AO, Hedberg P, Pereira JPV, Zazzi M, et al
    Increased In-Hospital Mortality in Immunocompromised Individuals Hospitalized With COVID-19 During the Global Pandemic: A Multinational Cohort Study in the EuCARE Project.
    J Infect Dis. 2026;234:e496-e505.
    PubMed         Abstract available

  13. FREYN AW, Budigi Y, Girard B, Santos G, et al
    Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies.
    J Infect Dis. 2026 Jun 4:jiag248. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  14. ZHANG L, Chen N, Eichmann A, Nehlmeier I, et al
    The conserved QTQTX motif in the SARS-CoV-2 spike protein is dispensable for cleavage and lung cell entry of the emerging variant BA.3.2.
    J Virol. 2026 Aug 5:e0069126. doi: 10.1128/jvi.00691.
    PubMed         Abstract available

  15. RIOS CARRASCO M, Guerreiro Cabana MF, Kovacs E, Ducarne Z, et al
    Acquisition of specific human respiratory tract binding by 2.3.4.4b H5N1 hemagglutinins requires multiple mutations.
    J Virol. 2026;100:e0106526.
    PubMed         Abstract available

  16. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed         Abstract available

  17. STADLER E, Mordant F, Gartner M, Docken SS, et al
    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.
    J Virol. 2026 Aug 27:e0082326. doi: 10.1128/jvi.00823.
    PubMed         Abstract available

  18. LIU G, Chen J, Wu F, Wei P, et al
    Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.
    J Virol. 2026 Aug 28:e0059926. doi: 10.1128/jvi.00599.
    PubMed         Abstract available

  19. XIE E, Schubert M, Reeb J, Seligmann B, et al
    Arp2/3 complex-dependent actin remodeling is required for efficient RSV uncoating in A549 cells.
    J Virol. 2026;100:e0111726.
    PubMed         Abstract available

  20. ULLAH R, Chen W, Zhang L, Guo C, et al
    Interaction between DEAD-box RNA helicase 10 and influenza PB1 polymerase selectively regulates influenza A virus replication.
    J Virol. 2026 Sep 22:e0081526. doi: 10.1128/jvi.00815.
    PubMed         Abstract available

  21. LEMUS-REYES JI, Fernandez-Quintero ML, Ayala E, Swanson OM, et al
    Antigenic and structural analysis of the influenza hemagglutinin lateral patch.
    J Virol. 2026 Sep 23:e0126526. doi: 10.1128/jvi.01265.
    PubMed         Abstract available

  22. PARK H-S, Matsuoka Y, Santos C, Duncan EF, et al
    Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters.
    J Virol. 2026 Sep 24:e0093826. doi: 10.1128/jvi.00938.
    PubMed         Abstract available


    PLoS One

  23. SODERSTROM LINDSTROM H, Norstrom SH, Tang C, Lindberg RH, et al
    Occurrence of influenza antivirals and resistance development in influenza A viruses in aquatic environments: A risk assessment.
    PLoS One. 2026;21:e0358447.
    PubMed         Abstract available

  24. OHLSON A, Rehn M, Kuhlmann Berenzon S, Sturegard E, et al
    Evaluation of wastewater SARS-CoV-2 surveillance for monitoring COVID-19 trends and early warning in Sweden, 2023-2024.
    PLoS One. 2026;21:e0358326.
    PubMed         Abstract available

  25. VAN KOEVERING K, Hong Y, Kleinberg J
    Social tectonics: Rapid organization of online COVID communities.
    PLoS One. 2026;21:e0355369.
    PubMed         Abstract available

  26. VARGA C
    Spatiotemporal clustering of highly pathogenic avian influenza (HPAI) H5N1 at the wild waterfowl-poultry interface: Vector-specific spillover risks in the U.S., 2022-2025.
    PLoS One. 2026;21:e0345354.
    PubMed         Abstract available

  27. ZHANG Y, Zhang Y, Zhao C, Xu X, et al
    Quantitative assessment of china's policies on the online sale of prescription drugs.
    PLoS One. 2026;21:e0358484.
    PubMed         Abstract available

  28. AICHBERGER MC, Fetz K, Leong S, Kim HS, et al
    Discrimination and technology-based disease control.
    PLoS One. 2026;21:e0357004.
    PubMed         Abstract available

  29. FERNANDEZ-PINEDA M, Swift A, Dolbier C, Swanson M, et al
    Navigating grief and healthcare: Mixed-methods study on patient experiences of miscarriage during COVID-19.
    PLoS One. 2026;21:e0359158.
    PubMed         Abstract available

  30. BIR C, Widmar NO, Wolf CA, Sheridan T, et al
    Societal values versus individual rights with respect to public health related practices during the COVID-19 pandemic in the U.S.
    PLoS One. 2026;21:e0358741.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  31. MAROUGKA K, Leiva-Rebollo R, Hofma F, van Dijk A, et al
    Substitutions affecting the HA-NA-receptor balance preceded the emergence of the pandemic 2009 H1N1 virus.
    Proc Natl Acad Sci U S A. 2026;123:e2609870123.
    PubMed         Abstract available


    Vaccine

  32. SCHAFFNER W, Gravenstein S, Kissler S, Cornely OA, et al
    Multicomponent vaccination against seasonal influenza and COVID-19: a strategy to address the continued global burden of disease in adults.
    Vaccine. 2026;93:129082.
    PubMed         Abstract available


    Virology

  33. ROWE T, Ross TM
    Transcriptional decoupling of the epithelial-immune bridge is associated with suboptimal influenza B virus immunogenicity.
    Virology. 2026;625:111075.
    PubMed         Abstract available


    Virus Res

  34. WU Q, Wang ZZ, Wang ZM, Wang YH, et al
    Development and validation of a broadly cross-reactive polyclonal antibody as capture antibody for pan human beta coronavirus antigen detection.
    Virus Res. 2026;372:199786.
    PubMed         Abstract available

  35. MANEESRIWONGUL W, Deesamer S, Butsing N
    Factors influencing Thai parents' COVID-19 vaccine acceptance for their children: Vaccine attitudes, beliefs, and children's past influenza vaccination.
    Virus Res. 2026 Sep 20:199805. doi: 10.1016/j.virusres.2026.199805.
    PubMed         Abstract available

  36. JANG Y, Cha RM, Park MJ, Kim JM, et al
    Genetic Diversity of Clade 2.3.4.4b H5Nx High Pathogenicity Avian Influenza Viruses Detected in Korea During the 2025-2026 Winter Season and Pathogenicity of H5N1 and H5N9 Viruses.
    Virus Res. 2026 Sep 22:199807. doi: 10.1016/j.virusres.2026.199807.
    PubMed         Abstract available

Friday, September 25, 2026

Modelling #assessment of the different #paths of between-farm #transmission of avian #influenza HPAI in Northern #Italy in 2021--2022

 


Abstract

We propose a stochastic epidemic model to describe the spread of avian influenza in a network of poultry farms. We consider three main paths of infection transmission between poultry farms: from nearby farms, mainly through airborne diffusion; from farms belonging to the same company, through shared veterinarians, forage providers and similar; from undetected small farms or wildlife. From the parameter estimation, based on a modified Expectation-Maximization algorithm, we infer that approximately 63% of the farms were infected from nearby ones, with an infection force declining with distance; of these, more than one third belonged to the same company of the estimated infector. About 20% were infected from premises belonging to the same company but farther away than the distance threshold of 2 km; the remaining ones from wildlife or unidentified sources. These estimates have been validated by a comparison with genetic data, available for a subset of the farms: the genetic distance between two farms identified, with high probability, as an infector-infectee pair is much lower than between random pairs. These results may help in the implementation of tailored prevention and control measures for future outbreaks.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Fondazione Caritro (Cassa di Risparmio di Trento e Rovereto), Post-Doc 2024 project ``Modelli matematici di malattie infettive piu` ospiti e popolazioni eterogenee: applicazioni all'influenza aviaria''

Source: 


Link: https://doi.org/10.64898/2026.09.19.752832

____

Thursday, September 24, 2026

Field #Investigation of #Bundibugyo Virus Disease (BDBV) #Outbreak in Ituri Province, #DRC: ... An Outbreak Investigation Review

 


Abstract

Background: 

The 2026 outbreak of Bundibugyo Ebola virus disease (BDBV) in eastern Democratic Republic of the Congo (DRC), centered in Ituri Province, represents the largest documented outbreak caused by Bundibugyo ebolavirus since its discovery in Uganda in 2007. The outbreak evolved within a complex humanitarian setting characterized by armed conflict, population displacement, mining-related migration, weak health systems, extensive population mobility, and an infodemic environment marked by misinformation and reduced public trust. We conducted a field investigation to assess epidemiological, operational, laboratory, infection prevention and control (IPC), community engagement, risk communication, and infodemic management challenges and identify priority interventions to strengthen outbreak control. 

Methods: 

A rapid field assessment was conducted between 12–15 June 2026 in Bunia, Rwampara Health Zone, and the Ituri Provincial Public Health Laboratory. Data were collected through direct observation, review of surveillance and laboratory reports, health facility assessments, stakeholder interviews, and analysis of outbreak response indicators. Epidemiological trends, surveillance performance, laboratory capacity, clinical care, IPC activities, logistics, risk communication, community engagement, and infodemic management approaches were evaluated. 

Results: 

As of 12 July 2026, the outbreak had resulted in 1926 laboratory-confirmed cases and 702 deaths, corresponding to an overall case fatality rate (CFR) of 36.4% across affected provinces. Ituri Province remained the epicenter, accounting for 90.8% of confirmed cases (1705/1877) and 85.5% of reported deaths (577/675). During the preceding 24 h, 53 new confirmed cases and 30 deaths were reported, including 20 community deaths (66.7%), highlighting persistent delays in detection, referral, and access to care. Surveillance systems identified 766 alerts, of which 678 (88.5%) were investigated, resulting in 235 suspected cases. Contact tracing remained a major challenge, with only 64.4% (4171/6475) of registered contacts successfully followed, below the recommended ≥95% target. Laboratory activities included testing of 137 specimens, with 29 positive results and an overall positivity rate of 21.2%. Decentralized molecular diagnostic platforms improved access to testing; however, data inconsistencies, delayed investigations, and gaps in outcome classification affected response monitoring. Major operational challenges included limited treatment capacity, high occupancy of Ebola treatment centres, shortages of trained personnel and IPC supplies, insecurity affecting response teams, and insufficient preparedness in newly affected areas. Community resistance, attacks on burial teams, detention of frontline responders, misinformation, and rumors contributed to delayed care-seeking, reduced acceptance of public health measures, and incomplete cooperation with contact tracing. Risk communication and community engagement efforts were constrained by limited outreach capacity, language barriers, low trust, and inadequate systems for rumor detection and infodemic response. 

Conclusions: 

The ongoing BDBV outbreak in eastern DRC demonstrates the difficulty of controlling Ebola transmission in conflict-affected and socially complex settings. Sustained transmission, community deaths, geographic expansion, and operational constraints highlight the urgent need to strengthen surveillance, contact tracing, laboratory systems, IPC capacity, clinical care, and integrated risk communication and infodemic management strategies. Building trust through community-centered approaches, proactive misinformation management, and engagement of trusted local actors will be essential to accelerate outbreak containment and strengthen preparedness across the Great Lakes region.

Source: 


Link: https://doi.org/10.3390/idr18050100

____

#Oya Virus in a Patient with Severe #Hepatitis, #Enteritis, and #Coagulopathy

 


Abstract

Oya virus, an orthobunyavirus, was identified in a 54-year-old woman who had sepsis-like symptoms, including leukocytosis, thrombocytopenia, elevated liver-function values, and disseminated intravascular coagulation.

Source: 

Link: https://doi.org/10.1056/NEJMc2602616

____

Wednesday, September 23, 2026

#Estimation of the #transmission #dynamics of #H5N1 HPAI #outbreak in a dairy #herd using a modeling approach

 


Abstract

The emergence of Highly Pathogenic Avian Influenza (HPAI 2.3.4.4b) in dairy herds in 2024 across 19 states in the United States of America has raised concerns regarding the potential national and global zoonotic impact. All recent modeling efforts implemented homogenous cattle-to-cattle (both intra and inter-herd) transmission models which did not capture the real-world heterogeneity in mixing of animals, individual variations in susceptibility and infectiousness and clinical incidences across pens and lactation groups. The aim of this study was to develop a heterogenous transmission model to estimate the epidemiological parameters for intra-herd HPAI transmission on Californian dairies. We developed a validated stochastic agent-based model to estimate the epidemiological parameters for intra-herd HPAI transmission on California dairies. The hierarchical agent-based model also parameterized stochastic cattle movements within-herd to simulate real dairy management practices. A cow-level SEIR transmission approach was assumed during the outbreak. A novel Bayesian Optimizer with Gaussian Process (BO-GP) was fitted to the agent-based model for validation which converged within 25-40 iterations (out of 100 per farm) with minimal loss over two distinct error metrics, namely, Poisson loss function and temporal distance metric. Our optimized simulations estimated an average R0 was around 10.7-10.8 across all farms within the first 15 days of observed outbreak on four dairy farms with a mean effective transmission rate of 4.5% per contact between susceptible and infectious cows within each pen. Our model demonstrated that the movement of cows between pens ensured localized clusters of outbreaks within the sub-herds (pen population) that prolonged the overall outbreak within farms. We estimated the total duration of infection between 14.5 and 28 days, which is higher than the estimates from the homogenous models. With an integrated hierarchical agent-based model combined with Bayesian approximation, we produced actionable insights on the epidemiology of intra-farm spread of HPAI within cow herds, thereby guiding both future model development and applied disease control strategy.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

Animal and Plant Health Inspection Service (USDA-APHIS), AP25VSD&B000C007

Source: 


Link: https://doi.org/10.64898/2026.09.22.753543

____

Comparison of #Baloxavir-Based Combinations and Monotherapies for Treating #Influenza #H5N1 Clade 2.3.4.4b Virus #Infection in Mice

 


Abstract

Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus continues to cause animal outbreaks and sporadic zoonotic infections. In a mouse model of lethal influenza disease, we compared oseltamivir, baloxavir, and molnupiravir monotherapies with 2-drug combinations. Baloxavir-based combinations improved survival, reduced lung viral loads, and prevented extrapulmonary dissemination, supporting H5N1 preparedness strategies.

Source: 


Link: https://doi.org/10.3201/eid3210.260186

____

Tuesday, September 22, 2026

A single-cycle, recombinant VSV #platform #Nipah #vaccine cross-protects against #Hendra virus in nonhuman #primates

 


Abstract

Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic paramyxoviruses that produce severe, often fatal disease in humans and animals. Zoonotic spillover of these henipaviruses from the Pteropid bat natural reservoir occurs near-annually in Southeast Asia and Oceania. Outbreaks of NiV disease frequently exceed case fatality rates of 75%, and person-to-person transmission makes controlling outbreaks in low-resource environments challenging. HeV is less transmissible between humans; however, the overall mortality rate is 57%. Approaches to human vaccine development have largely focused on NiV given the larger case burden, and immunogen selection has centered on display of the NiV attachment (G) or fusion (F) surface glycoproteins. However, experimental vaccines displaying these NiV antigens have failed to uniformly cross-protect against HeV disease in preclinical models. The HeV (G) antigen was shown to cross-protect against both HeV and NiV when delivered in a protein subunit form; however, attempts to utilize mRNA or canarypox vectors failed to achieve equivalent protection. We previously developed and evaluated a single-cycle recombinant vesicular stomatitis virus-vectored vaccine displaying the (G) glycoprotein of Nipah virus strain Bangladesh (NiV-B). This experimental vaccine (G*rVSV∆G-NiV-G) demonstrated ideal characteristics of rapid and durable protection against NiV-B challenge in nonhuman primates. In the present work, we show that the G*rVSV∆G-NiV-G vaccine cross-protects against lethal HeV challenge, with the protective response driven by a balance of both cell-mediated and humoral compartments.

Source: 


Link: https://doi.org/10.1371/journal.ppat.1014646

____

Highly Pathogenic Avian #Influenza Virus #H5 in #Cetaceans, #Brazil

 


Abstract

We identified highly pathogenic avian influenza virus subtype H5 in stranded dolphins along the coastline of Brazil during 2023–2025. Infected animals included species classified as vulnerable or endangered. Our results highlight the need for ongoing surveillance of cetaceans susceptible to viral infections, which pose an additional threat to threatened species.

Source: 


Link: https://doi.org/10.3201/eid3210.260051

____

Emergence of short-lived #meningococci causing focal #epidemics can be associated with #gene #transfer from carriage-associated #Neisseria

 


Abstract

In March 2026, an unusually large outbreak of invasive meningococcal disease (IMD) in Kent, UK, was linked to attendance at one nightclub over a single weekend. The outbreak organism was a Neisseria meningitidis variant belonging to the longstanding hyperinvasive genotype, cc41/44. Using genome analysis of six isolates from patients, alongside >48,000 meningococcal genomes, we investigated whether the outbreak variant had acquired traits potentially contributing to the highly invasive phenotype. The six isolates were capsular group B, sequence type (ST-)485, and essentially indistinguishable, consistent with the focal nature of the outbreak. Compared with their closest available relatives, we found changes mediated by phase variation, nucleotide variation, and horizontal gene transfer (HGT) involving adhesins, iron-acquisition systems (including Transferrin and Lactoferrin binding proteins, and FetA), and Type IV pili (Tfp), factors which affect bacteria-bacteria and bacteria-host interactions. These changes occurred in a ST-485 sub-lineage that expressed capsule at high levels and a PorA porin with a truncated surface-exposed epitope, both of which are predicted to reduce immune recognition. Donors for the HGT events were predominantly carriage-associated N. meningitidis and Neisseria cinerea. We show that meningococcal variants responsible for previous focal outbreaks have not been seen subsequently. We propose that focal outbreaks of IMD are caused by meningococcal variants that may have acquired traits from non- or less invasive organisms, but subsequently these variants disappear, as their highly invasive phenotype is inconsistent with sustained transmission. Ongoing disease surveillance alongside carriage studies are therefore essential to inform public health risk and manage epidemic IMD.


Competing Interest Statement

CMT and RME are inventors on patents for meningococcal vaccines. JPD is a co-founder and Director of Immunosig Ltd, a company which offers antigen microarray-based services. JL, RB, SAC and XB perform contract research on behalf of UKHSA for GSK, Pfizer, Sanofi and Serum Institute of India.


Funder Information Declared

Wellcome Trust, https://ror.org/029chgv08, 218205/Z/19/Z, 221924/Z/20/Z

NIH Common Fund, https://ror.org/001d55x84, R01AI127793

Source: 


Link: https://doi.org/10.64898/2026.09.17.752363

____

Occurrence of #influenza #antivirals and #resistance development in #influenza A viruses in aquatic #environments: A risk assessment

 


Abstract

Influenza antivirals (IAs) have been detected in aquatic environments inhabited by dabbling ducks, the natural reservoir of influenza A virus (IAV), raising concerns about the development of antiviral resistance. Because novel human IAV strains often contain genetic material of avian origin, this may contribute to resistance in viruses with pandemic potential. This study aimed to assess the environmental risk posed by four IAs—oseltamivir carboxylate (OC), zanamivir (ZA), peramivir (PE), and amantadine (AM)—based on their potential for environmental release, environmental stability, and induction of antiviral resistance. The assessment combined data from new experiments on (1) environmental release and (2) environmental stability of PE, AM, OC, and ZA, with results from previously published in vivo experiments in a mallard model examining (3) resistance development to OC, PE, and ZA in IAV. The risk of environmental release was assessed as high for OC, AM, and PE, and very high for ZA. Environmental stability ranged from very high to low, in the order PE > AM > OC > ZA. The potential to induce resistance in IAV was similar for PE and OC, and lower for ZA. Overall, the environmental risk ranking was PE > OC > ZA, with PE and OC posing the highest risks. Prudent use of IAs requires balancing the risk of resistance development against clinical benefit. In cases of complicated influenza or in high-risk patient groups, the clinical benefits are substantial and justify IA use. However, in uncomplicated influenza among otherwise healthy individuals, the clinical benefit is limited, and the risk of resistance development should be carefully considered. Among the evaluated antivirals, ZA showed the lowest environmental risk and should be preferred when feasible.

Source: 


Link: https://doi.org/10.1371/journal.pone.0358447

____

#Oropouche virus disrupts #neurodevelopment and exhibits #congenital infection potential

 


Abstract

Oropouche virus (OROV) historically caused a self-limiting disease, yet recent strains have been clinically linked to congenital infection and neurodevelopmental disease. These observations highlight the need to study OROV as a congenital pathogen. Here, using both a historical and currently circulating strain, we show OROV infects neurons across differentiation states in human forebrain organoids. Compared with the neurotropic congenital pathogen Zika virus (ZIKV), OROV exhibits a heightened capacity for neuroinfection and pathology in both forebrain organoids and neonatal mice. The increased permissiveness of OROV is driven, in part, by a broader neuronal tropism and a relative insensitivity to neuronal type I interferon-mediated antiviral responses. Consistent with clinical observations, neonatal neuroinfection results in rapid and severe neuropathology marked by cerebral hemorrhage. Finally, using a transient type I interferon-blockade model, we demonstrate that OROV can productively infect the murine placenta and cause fetal growth restriction. Together, our complementary models support a unified framework in which placental and fetal barriers limit productive fetal brain infection, yet OROV exhibits marked neurotropism and neuropathogenic potential upon gaining access to developing neural tissues. These findings reinforce the need for vigilant monitoring of OROV as an emerging pathogen associated with adverse pregnancy outcomes and congenital disease.

Source: 


Link: https://doi.org/10.1038/s41467-026-77859-5

____

Molecular #Epidemiology and #Evolution of Swine #Influenza A Viruses, #Vietnam, 2020–2024

 


Abstract

Swine influenza A viruses (IAV-S) caused the 2009 H1N1 pandemic and pose a future zoonotic and pandemic threat. Vietnam represents a critical hotspot for IAV-S emergence within East and Southeast Asia, with dense swine and human populations and intensive livestock trade. We conducted genomic surveillance of IAV-S in Vietnam during 2020–2024, extending previous surveillance from 2013–2019. We identified multiple co-circulating H1 and H3 clades, including pandemic H1N1, Eurasian avian-like, and European lineages, by conducting phylogenetic analysis of 56 IAV-S isolates (21 H1N1, 31 H1N2, and 4 H3N2). Three H1 clades persisted exclusively in Vietnam, circulating up to 12 years. Phylogeographic analysis revealed multiple independent introduction events from North America, Europe, China, Thailand, and Cambodia. We detected extensive reassortment that frequently involved pandemic H1N1 virus internal genes. We identified several lineage-specific mutations associated with mammalian adaptation. Our findings underscore the ongoing IAV-S evolution and need for sustained surveillance in Vietnam.

Source: 


Link: https://doi.org/10.3201/eid3210.260593

____

Serological #Evidence of Widespread #Exposure to #H5 Avian #Influenza Virus in #Arctic #Foxes in #Svalbard, Norway

 


Abstract

The continued circulation of H5 clade 2.3.4.4b highly pathogenic avian influenza virus (HPAIV) has caused extensive mortality in wild bird populations worldwide with increasing spillover to mammals. In 2022, H5 HPAIV emerged in Svalbard, Norway, with subsequent detections in wild birds, walruses, polar bears, and arctic foxes. To understand the population-level exposure among Svalbard arctic foxes, we analysed body fluids from carcasses trapped in 2006-2015 (n = 56), 2023-2024 (n = 112), and 2024-2025 (n = 94) for antibodies to H5 avian influenza (anti-H5), influenza A nucleoprotein (anti-NP), and neuraminidase subtypes using ELISAs, haemagglutination inhibition (HI), and a multiplex assay. Only three samples from 2006-2015 tested positive for anti-H5 and were interpreted as false positives. In 2023-2024, seropositivity for anti-H5 was high (95%), supported by a lower anti-NP seropositivity (85%) and antibody profiles consistent with mixed H5N1 (42%) and H5N5 (52%) exposure. In 2024-2025, anti-H5 and anti-NP seroprevalences remained high (83% and 57%), with H5N5 (87%) exposure predominating over H5N1 (3%). A subset of anti-H5-positive samples tested positive by HI (2023-2024: 30%; 2024-2025: 14%). Juveniles with exposure limited to the previous season had higher odds of anti-H5 seropositivity in 2023-2024 than in 2024-2025 (OR 5.5). Analysis of paired lung extracts from a subset of individuals (n = 63) yielded results concordant with body fluids, using an indirect anti-H5 ELISA adapted for carnivores. Our findings demonstrate widespread H5 virus exposure. Together with occasional reports of progression to fatal HPAI, this highlights the need for continued population monitoring to evaluate ecological consequences.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

European Commission, https://ror.org/00k4n6c32, 101132473, 101084171

Dutch Research Council, ENWPP.SK.2025.001

Source: 


Link: https://doi.org/10.64898/2026.09.17.752278

____

Monday, September 21, 2026

Limited added #benefit of seasonal #influenza #vaccination before #H5 vaccination in mice and #ferrets challenged with #H5N1

 


ABSTRACT

Limited A(H5)-specific vaccine supply is expected early in a potential A(H5N1) pandemic, raising the question of whether licensed seasonal influenza vaccines could enhance protection when administered before A(H5) vaccination. We evaluated this strategy in mouse and ferret models using clade 2.3.4.4b A(H5N1) viruses. Seasonal influenza vaccination induced antibodies to seasonal haemagglutinins but did not induce detectable antibodies against A(H5) and did not consistently enhance A(H5)-directed antibody responses after A(H5) vaccination. In lethal challenge studies, seasonal vaccine priming before A(H5) vaccination was associated with improved outcomes compared with A(H5) vaccination alone in one of three mouse experiments, but this effect was not observed in the other two mouse experiments or in ferrets. These findings suggest that seasonal influenza vaccine priming provides limited added benefit to A(H5) vaccine-mediated protection against A(H5N1) under the conditions tested.

Source: 


Link: https://doi.org/10.1080/22221751.2026.2731495

____

Epidemiological #investigation of #Shuni virus #infections in #hospitals in two provinces of South Africa (2019–2021) using molecular and serological surveillance

 


Abstract

Shuni Virus (SHUV) is a reemerging zoonotic orthobunyavirus in the Peribunyaviridae family associated with neurological infections and birth defects in humans and animals in Africa and has emerged in the Middle East in the past 10 years. Limited epidemiological data exist in humans, partially due to a lack of clinical awareness and availability of diagnostic assays to determine the incidence of clinical cases and seroprevalence in the population. The goal of this study was to establish serologic and molecular diagnostic assays for SHUV for hospital-based surveillance and to investigate the clinical epidemiology in humans in South Africa. The incidence of SHUV infections was investigated in patients with acute fever of unknown cause with or without neurological signs (AFDUC/N) during the arbovirus season (January-June, 2019–2021). IgM and IgG ELISAs for SHUV were established using baculovirus-expressed glycoproteins and validated against virus-neutralization tests (VNT) positive sera. Orthobunyavirus quantitative RT-PCR (RT-qPCR) and IgM ELISA were used to identify acute infections, and IgG ELISA to define the seroprevalence in patients and healthy control groups in hospitals in Gauteng and Mpumalanga provinces in South Africa. In total, 3/349 (0.84%) AFDUC/N cases tested positive by RT-qPCR and confirmed as SHUV by sequencing. In total, 22/225 (9.7%) AFDUC/N patients had SHUV neutralising antibodies (VNT), of which 11/22 (50.00%) were IgM positive, with an IgM seropositivity of 4.89% (11/225 (4.89%)). Of the RT-PCR and double IgM + VNT+ patients, 60% presented with seizures and 40% with meningitis, of which 36.36% were children and 63.63% were adults, respectively. In total, 9/112 (8%) of the healthy control group tested positive on the IgG ELISA assay. These findings suggest that SHUV is a missed cause of acute neurological infections in hospitalized children and adults in South Africa and should be investigated in humans in Africa and other regions.

Source: 


Link: https://doi.org/10.1371/journal.pntd.0014738

____

Saturday, September 19, 2026

#Coronavirus Disease Research #References (AMEDEO, September 19 '26)

 


    Am J Obstet Gynecol

  1. HABBOUS S, Surani A, Leyland NA, Murji A, et al
    Uptake and outcomes associated with outpatient hysterectomy in Ontario, Canada.
    Am J Obstet Gynecol. 2026 Sep 18:S0002-9378(26)00500.
    PubMed         Abstract available


    Antiviral Res

  2. DU PONT V, Han D, Li J, Rodriguez L, et al
    Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions.
    Antiviral Res. 2026;255:106533.
    PubMed         Abstract available

  3. MARTINEZ-ARRIBAS B, Diaz-Gonzalez R, Weaver J, Walden M, et al
    Identification of 1,2-dihydroquinazolin-2-ones kinase inhibitors as anti-coronavirus agents.
    Antiviral Res. 2026 Sep 15:106534. doi: 10.1016/j.antiviral.2026.106534.
    PubMed         Abstract available

  4. NAGAHAWATTA DP, Jeong SH, Liyanage NM, Jayawardena TU, et al
    Marine phlorotannins block SARS-CoV-2 entry via ACE2 and attenuate pulmonary inflammation in K18-hACE2 transgenic mice.
    Antiviral Res. 2026 Sep 15:106532. doi: 10.1016/j.antiviral.2026.106532.
    PubMed         Abstract available


    BMJ

  5. WISE J
    Covid-19 inquiry: Additional psychological support for doctors would be rolled out in future pandemic, government says.
    BMJ. 2026;394:e100866.
    PubMed        

  6. WILLMAN D
    US officials knew covid vaccine safety system was flawed-but turned aside the FDA doctor who alerted them.
    BMJ. 2026;394:e100806.
    PubMed        


    Emerg Infect Dis

  7. DUTCHER HA, Antkiewicz DS, Roguet AJ, Shafer MM, et al
    Implementation and Early Outcomes of Laboratory Proficiency Testing Program for the National Wastewater Surveillance System, United States, 2024.
    Emerg Infect Dis. 2026;32:19-25.
    PubMed         Abstract available

  8. BI K, Sandoval M, Nguyen T, Perez I, et al
    Temporal Alignment of Wastewater Signals with Clinical Indicators of Respiratory Illness Postpandemic, Texas, USA.
    Emerg Infect Dis. 2026;32:43-52.
    PubMed         Abstract available

  9. MARK-CAREW M, Bias M, Reckling S, Madhobi K, et al
    Progress and Expansion of the National Wastewater Surveillance System, United States, 2020-2024.
    Emerg Infect Dis. 2026;32:3-13.
    PubMed         Abstract available

  10. LEFFERTS B, Leary A, Bruden D, Blake I, et al
    Wastewater Respiratory Virus Surveillance in Remote Community, Alaska, USA, 2022-2024.
    Emerg Infect Dis. 2026;32:71-79.
    PubMed         Abstract available

  11. MOORE JT, Rose-McCully K, Valencia D, Turner H, et al
    Exploration of Public Perceptions of Wastewater Surveillance, United States, June 2024.
    Emerg Infect Dis. 2026;32:115-118.
    PubMed         Abstract available


    Eur J Radiol

  12. SCHMIDT K, Steinberger M, Woellert S, Klein M, et al
    CT radiation exposure of emergency department patients before, during and after the COVID-19 pandemic.
    Eur J Radiol. 2026;205:113211.
    PubMed         Abstract available


    Int J Infect Dis

  13. HERRERO RL, Jimenez PM, Del Olmo DO, Prieto-Utrera RD, et al
    Epidemiological trends in sepsis in Spain: incidence, in-hospital mortality, and healthcare burden (2017-2022).
    Int J Infect Dis. 2026 Sep 16:109121. doi: 10.1016/j.ijid.2026.109121.
    PubMed         Abstract available

  14. XU M, Huang Y, Ma H, Wu Z, et al
    A Multi-model Counterfactual Analysis of Human Brucellosis in China: Spatiotemporal Epidemiology and Heterogeneous Pandemic-associated Deviations in 2020.
    Int J Infect Dis. 2026 Sep 15:109119. doi: 10.1016/j.ijid.2026.109119.
    PubMed         Abstract available


    J Infect

  15. ORTEGA-FRANCISCO S, Prudente de Aquino MT, Chiuppesi F, Gutierrez-Franco MA Jr, et al
    Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity.
    J Infect. 2026;93:106855.
    PubMed         Abstract available

  16. HARRIS R, Thirard R, Iftikhar H, Middleditch A, et al
    Corrigendum to "Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: A randomised controlled trial" [J Infect 93 (2026) 106784].
    J Infect. 2026;93:106853.
    PubMed        

  17. BERES SB, Pagnossin D, Olsen RJ, Long SW, et al
    Clinical and population genomic epidemiology of invasive group A streptococcus in Scotland, 2014-2024.
    J Infect. 2026 Sep 18:106860. doi: 10.1016/j.jinf.2026.106860.
    PubMed         Abstract available


    J Med Virol

  18. YANG T, Zhang R, Qin S, Zheng Y, et al
    Cross-Neutralization Responses and Persistent Symptoms After SARS-CoV-2 Breakthrough Infections.
    J Med Virol. 2026;98:e71153.
    PubMed         Abstract available

  19. TURANLI EE, Yildirim Arslan S, Dinc F
    Clinical Outcomes in Pediatric COVID-19 Across Two Time Periods: The Role of Coinfection, Age, and Inflammatory Markers.
    J Med Virol. 2026;98:e71156.
    PubMed         Abstract available


    J Virol

  20. BUGA CC, Valerio M, Alenquer M, Pires de Miranda M, et al
    Insights into the mechanism of action of the bipartite fusion module of SARS-CoV-2 spike protein.
    J Virol. 2026 Sep 15:e0068826. doi: 10.1128/jvi.00688.
    PubMed         Abstract available


    Nature

  21. VARILLY P, Schifferli M, Yang K, Cronan P, et al
    Scalable near-real-time Bayesian phylogenetics for outbreaks with Delphy.
    Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11012.
    PubMed         Abstract available

My New Space

Most Popular Posts